reports
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma Approximately 71% of Stockholders Voted in Favor of the TransactionDiffusion Announces 1-for-1.5 Reverse Stock SplitMerger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. (“EIP”), and a reverse stock split of o...
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to ...
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b clinical data and to the end of 2024 Transaction has unanimous support of both EIP Pharma and Diffusion Boards of Directors...
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opp...
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities LifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at 2022 Annual Meeting New Director to be Appointed to Diffusion Board if Strategic Transaction Not Completed by mid-2023 CHARLOTTESVILLE, Va., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver o...
Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting St...
Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-Dealing Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review processDiffusion received bids from more than 15 companies participating in review processLifeSci invited to participate in review process on same terms as all other bidders following submission of client’s unsolicited offe...
Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results...
Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Announced Thorough Evaluation of a Range of Potential Strategic OpportunitiesContinued GBM Study Start-up ActivitiesEnded Quarter with $25.9 million in Cash, Cash Equivalents and Marketable Securities CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced ...
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic R...
Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank LifeSci Capital LifeSci-affiliated Fund Commences Proxy Contest for Control of the Diffusion Board Following Rejection of Client’s Offer Company Believes LifeSci Proxy Campaign is Attempt to Circumvent Strategic Review Process Date of Diffusion’s 2022 Annual Meeting of Stockholders Set for Dec...
Diffusion Pharmaceuticals Announces Strategic Review Process to Evalua...
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC CHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that its Board of Directors (the “Board”) has authorized a thorough review and evaluation of a range of potential strategic opportunities in the inte...
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Result...
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update • Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022• Reported Positive Effects in TSC Altitude Trial• Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities• Expected Cash Runway into First Quarter of 2024 CHARLOTTESVILLE, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the ...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with G...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”) patientsCompany to evaluate effects of TSC on tumor oxygenation using an innovative positron emission tomography (“PET”) hypoxia imaging methodology with data expected within one year of study initiationDiffusion previously obtained Orph...
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise intervalPositive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to measurements at the end of the exercise intervalTSC was safe and well-tolerated by all subjects with no serious adverse events reported CHARLOTTESVILLE, Va., June 23, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that enhance the body’s abil...
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S.,...
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer Appointment brings 20 years of regulatory affairs experience and exceptional leadership capabilities CHARLOTTESVILLE, Va., May 18, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Raven Jaeger, M.S., has joined the Company as its Chief Regulatory Officer effective immediately. Ms. Jaeger will be responsible for dev...
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investm...
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., the Company’s President and Chief Executive Officer, will be presenting at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022. The presentation will ...
Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results...
Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update Completed Dosing in Altitude Trial; Topline Data Expected in June 2022Blinded, Interim Data to be Presented at UHMS Annual Scientific Meeting in May 2022Ended Quarter with $32.6 Million in Cash, Cash Equivalents and Marketable SecuritiesRegained Compliance with Nasdaq Bid Price Rule CHARLOTTESVILLE, Va., May 12, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’...
Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requi...
Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement. The Company was previousl...
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Pa...
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan Split Expected to be Effective for Trading Purposes as of Market Open on April 19, 2022 CHARLOTTESVILLE, Va., April 18, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that it will effect a 1-for-50 reverse stock split of its common stock. The reverse stock split is expected to become effective at 5:59 p.m. Easte...
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial Topline data expected within two months Blinded, interim data to be presented at the Undersea & Hyperbaric Medical Society’s Annual Scientific Meeting in May 2022 CHARLOTTESVILLE, Va., April 11, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced the final participant has completed dosing in its Altitude Trial. The Altitude...
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides ...
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update Altitude Trial Dosing Expected To Be Completed in 2Q2022; mid-2022 for ILD-DLCO TrialPhase 2 Hypoxic Solid Tumor Study Protocol Submission Planned to Support 2H22 Study Start$37.3M in Cash & Cash Equivalents as of Year-End; Expected to Fund Operations Through 2023 CHARLOTTESVILLE, Va., March 21, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to delive...
Diffusion Pharmaceuticals Expands its Scientific Advisory Board with t...
Diffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology Experts New SAB Members Bring Expertise in the Fields of Radiation Biology and Tumor Hypoxia CHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced a significant expansion of its Scientific Advisory Board (SAB) to include five prominent radiation and medical oncolo...
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Pa...
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022” CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- . (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced today that the Company will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering at JPM. All three events are scheduled alongside the J.P. Morga...
Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial
Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial Third of Three TSC Oxygenation Trials CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- . (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced it has dosed the first patients in its ILD-DLCO Trial. The trial will evaluate the Company’s lead product candidate, trans sodium crocetinate (“TSC”), in patients with previously diagnosed interstitial lung disease (“ILD”). “We...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.